anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In recent years, the incidence of autism has increased year by year, which has brought a heavy burden to society and families. For the special group of children with autism spectrum disorder, previous studies focused on the lack of comprehensive and accurate visual function characteristics and defects of this group. In the early stage, it was believed that there was a certain correlation between visual impairment and autism, and some patients with visual impairment were misdiagnosed as autism. Moreover, some studies have shown that the incidence of refractive errors and oblique amblyopia in autistic children is significantly higher than that in normal children. This study mainly includes two parts: On the one hand, investigate the autism children in Tianjin area to understand the incidence of eye diseases. On the other hand, children with eye problems were given relevant interventions, such as optometry, amblyopia training, strabismus surgery, etc., to assess the impact of the corresponding treatment on the quality of life of the children and their primary caregivers.
PURPOSE:To recover a water-soluble protein in high efficiency in an easily driable state by mixing a yolk liquid with an aqueous solution of a water-soluble substance such as water soluble cellulose derivative and recovering the supernatant liquid of the mixture. CONSTITUTION:Yolk liquid preferably diluted 2-5 times with water is mixed with an aqueous solution containing a substance selected from water-soluble cellulose derivative, PVA and cyclodextrin or the yolk liquid is brought into contact in heterogeneous state with a polymeric substance soluble under a condition shifted to alkaline side from pH 5.0-6.0 (e.g. copolymer of methacrylic acid and ethyl acrylate or methyl methacrylate or hydroxypropyl methylcellulose phthalate) to effect the separation of yolk lipoprotein as a precipitate. The supernatant liquid of the mixture is recovered to obtain the objective water-soluble protein. The process is suitable for the recovery of IgG antibody, IgM antibody, etc., from immunized chicken egg. The recovery can be carried out in high efficiency scarcely lowering the antibody titer.
The experienced participants(113 participants) who failed prior DAA treatments. They were allocated to cirrhotic (30 participants) and treated for 12 weeks.
It has been reported that effective catheter fixation will reduce the risk of catheter unavailability for specific reasons and the incidence of catheter-related complications. Intravenous cannulas are usually fixed with a thin board, a bandage, and tape. There is no standard way of using PIVC dressings in Turkey. After the catheter is inserted into the vein, gauze and a blaster, sterile transparent dressing materials, or just a blaster, are used to prevent contact of the fixed part and the area of intervention with the external environment. Transparent dressing used for catheter fixation contribute to a more comfortable evaluation of the catheter entry site. It has been suggested that the use of transparent film dressing may be effective in preventing and early detection of catheter-related complications. Moreover, it was concluded that due to the short duration of the procedure, it reduced the cost of manpower, and nurses could devote more time to other patients.
OBJECTIVE: Intraventricular baclofen has been reported as an alternative to intrathecal baclofen for managing refractory spasticity and dystonia in some circumstances. In this report, we described a frame-based stereotactic approach for precisely positioning of the infusion catheter into the third ventricle.
MATERIAL AND METHODS: High resolution contrast-enhanced anatomical MR sequences was acquired prior to surgery for pre-planning. Catheter trajectory was planned to pass from the lateral ventricle to the third ventricle through the Foramen of Monro. The surgical procedure was adapted from the frame-based deep brain stimulation surgery. The Touch-Loc kit (SceneRay, China) was used to temporarily secure the catheter in place during the surgery. From July 2022 to December 2022, three patients suffering from intractable spasticity and/or secondary dystonia received IVB successfully using the described technique.
RESULTS: No severe adverse events, including death, intracranial hemorrhage, infection, catheter migration or fracture, were documented at the last follow-up (range: 12‒24 months). Transient side effects included mild nausea following the initiation of infusion or the increase in infusion rate. All three patients responded to the IVB.
CONCLUSIONS: The described frame-based stereotactic technique for IVB catheter implant is feasible and could be quickly mastered by neurosurgeons in related fields. Larger prospective cohorts with longer follow-up periods are necessary to further evaluate the long-term safety and efficacy of this procedure.
Patients with end stage renal failure on haemodialysis must have a mechanism for achieving access to their vascular system for dialysis. Arteriovenous fistulas (surgically created connections between the artery and vein) are critical for the majority of patients. Not all the fistulas that are created work, a proportion fail early on and need to be revised or an alternative fistula created. A recent multicentre study demonstrated a 40% primary failure rate(1). In an attempt to increase the numbers of fistulae that reach maturation sufficient for dialysis access cannulation some renal centres apply GTN patches to the fistula at the time of surgery. It is thought that this works by increasing the size of the blood vessels and promoting blood flow through them and some preliminary work seems to support this(2).

The evidence for the use of GTN patches in arteriovenous fistula creation is theoretical or based on preliminary work rather than robust evidence. Similarly no evidence exists within the literature to determine the safety and definite efficacy of this procedure in this population. We propose to conduct a double-blinded randomised control trial to answer the study question: does the application of a GTN patch increase the venous outflow diameter post fistula formation and does this result in improved fistula patency.
The invention provides a method of producing differentiated cells, comprising causing a population of undifferentiated stems cells to differentiate, wherein the undifferentiated stems cells have a nucleic acid molecule of the structure P-X, wherein X is a sequence causing expression of a cell surface antigen, and P is a transcriptional control element operatively linked to X, such that the surface antigen is expressed in undifferentiated cells. Preferably, remaining undifferentiated cells are then depleted by combining the cells with a ligand specific for the antigen, for example and antibody or lectin. The invention also relates to a method of producing a cell population depleted of undifferentiated stem cells, comprising genetically altering undifferentiated stem cells with an nucleic acid molecule comprising the structure P-X as defined above, and depleting undifferentiated cells by combining the cells with a ligand specific for the antigen. In preferred embodiments, X encodes a glycosyltransferase, preferably an alpha(1,3)galactosyltransferase. P is preferably a promoter of telomerase reverse transcriptase (TERT) or an OCT-4 promoter. The invention also relates to a stem cell genetically modified to express a carbohydrate antigen not normally expressed by the cell. The stem cell may be modified by a construct containing the alpha(1,3)galactosyltransferase gene under the control of a TERT or OCT-4 promoter.
Tongue cancer has a very high incidence in China, and there is a need to develop new anti-tumour drugs against it. We synthesised 31 novel quinoline derivatives to test their anti-tumour activity. A compound referred to as "f25" was identified through screening for its high in vitro toxicity against an oral squamous carcinoma cell line (CAL-27). f25 exhibited significant cytotoxicity against CAL-27 cells (IC50 = 7.70 ± 0.58 μΜ). f25 also inhibited the migration and invasion of CAL-27 cells to a level comparable with that of the chemotherapy agent cisplatin. Moreover, f25 promoted the apoptosis of CAL-27 cells. Transcriptome sequencing and western blotting showed that the mechanism of action of f25 against CAL-27 cells involved the peroxisome proliferator-activated receptor (PPAR) signalling pathway. Specifically, f25 could bind to PPAR-α, PPAR-β, and PPAR-γ and increase their expression. In vivo experiments showed that treatment with f25 led to a reduction in tumour volume in nude mice without significant toxicity. Overall, this study highlights the potential of quinoline compounds (particularly f25) for the design and synthesis of anti-tumour drugs. It also underscores the importance of the PPAR signalling pathway as a target for potential cancer therapies.
The LEMON study (LEft Main Oct-guided iNterventions) is a prospective, multicentre, open-label, interventional , non-randomized trial that investigates the feasibility and efficiency of OCT guidance for left main PCI in 10 active French interventional cardiology centres. The aim of the study is the appliance of a pre-defined standardized protocol for LM PCI . The LM PCI strategy is guided by 3 OCT runs, according to a pre-determined protocol. The first OCT run (run1) is performed before any stent implantation, the second run (run2) is performed after the stent is implanted, POT (proximal optimization technique) is applied and side branch iss rewired through stent struts. The third run (run3) is performed after PCI optimization. In case of additional stent optimization, a supplementary OCT run is applied in order to assess final result.
FIELD: medicine, pharmacy. SUBSTANCE: composition has an effective amount of water-soluble salt or complex of acetylsalicylic acid in association with metoclopramide or one of its pharmaceutical salt as an active component and at least one pharmaceutically acceptable hydrophilic polymer in the amount providing the stabilization of metoclopramide. Invention proposes also the preparation based on the given composition. Preparation is obtained by mixing powders of composition followed by its granulating. EFFECT: increased stability of powdery composition. 18 cl, 1 tbl, 2 ex
Gout is a common autoinflammatory joint diseases characterized by deposition of monosodium urate (MSU) crystals which trigger an innate immune response mediated by inflammatory cytokines. IGF1R is one of the loci associated with both urate levels and gout susceptibility in GWAS to date, and IGF-1-IGF-1R signaling is implicated in urate control. We investigate the role of IGF-1/IGF1R signaling in the context of gouty inflammation. Also, we test the gout and urate-associated IGF1R rs6598541 polymorphism for association with the inflammatory capacity of mononuclear cells. For this, freshly isolated human peripheral blood mononuclear cells (PBMCs) were exposed to recombinant IGF-1 or anti-IGF1R neutralizing antibody in the presence or absence of solubilized urate, stimulated with LPS/MSU crystals. Also, the association of rs6598541 with IGF1R and protein expression and with ex vivo cytokine production levels after stimulation with gout specific stimuli was tested. Urate exposure was not associated with IGF1R expression in vitro or in vivo. Modulation of IGF1R did not alter urate-induced inflammation. Developing urate-induced trained immunity in vitro was not influenced in cells challenged with IGF-1 recombinant protein. Moreover, the IGF1R rs6598541 SNP was not associated with cytokine production. Our results indicate that urate-induced inflammatory priming is not regulated by IGF-1/IGF1R signaling in vitro. IGF1R rs6598541 status was not asociated with IGF1R expression or cytokine production in primary human PBMCs. This study suggests that the role of IGF1R in gout is tissue-specific and may be more relevant in the control of urate levels rather than in inflammatory signaling in gout.
IV Ceftaroline fosamil 15 mg/kg (or 600 mg if \> 40 kg) infused over 120 (± 10) minutes q8h (± 1 hour). The dose may vary with age.
Adult: The adult daily dosage of Amantadine Hydrochloride Capsules is 200 mg; two 100 mg capsules as a single daily dose. The daily dosage may be split into one capsule of 100 mg twice a day. If central nervous system effects develop in once-a-day dosage, a split dosage schedule may reduce such complaints. In persons 65 years of age or older, the daily dosage of Amantadine Hydrochloride Capsules is 100 mg. 

A 100 mg daily dose has also been shown in experimental challenge studies to be effective as prophylaxis in healthy adults who are not at high risk for influenza-related complications. However, it has not been demonstrated that a 100 mg daily dose is as effective as a 200 mg daily dose for prophylaxis, nor has the 100 mg daily dose been studied in the treatment of acute influenza illness. In recent clinical trials, the incidence of central nervous system (CNS) side effects associated with the 100 mg daily dose was at or near the level of placebo. The 100 mg dose is recommended for persons who have demonstrated intolerance to 200 mg of Amantadine Hydrochloride Capsules daily because of CNS or other toxicities. 

Pediatric Patients: 1 yr. to 9 yrs. of age:  The total daily dose should be calculated on the basis of 2 to 4 mg/lb/day (4.4 to 8.8 mg/kg/day), but not to exceed 150 mg per day. 

9 yrs.to12 yrs. of age: The total daily dose is 200 mg given as one capsule of 100 mg twice a day. The 100 mg daily dose has not been studied in this pediatric population. Therefore, there are no data which demonstrate that this dose is as effective as or is safer than the 200 mg daily dose in this patient population. 

Prophylactic dosing should be started in anticipation of an influenza A outbreak and before or after contact with individuals with influenza A virus respiratory tract illness. 

Amantadine Hydrochloride Capsules should be continued daily for at least 10 days following a known exposure. If Amantadine Hydrochloride Capsules are used chemoprophylactically in conjunction with inactivated influenza A virus vaccine until protective antibody responses develop, then it should be administered for 2 to 4 weeks after the vaccine has been given. When inactivated influenza A virus vaccine is unavailable or contraindicated, Amantadine Hydrochloride Capsules should be administered for the duration of known influenza A in the community because of repeated and unknown exposure. 

Treatment of influenza A virus illness should be started as soon as possible, preferably within 24 to 48 hours after onset of signs and symptoms, and should be continued for 24 to 48 hours after the disappearance of signs and symptoms.
The invention relates to daily chemical field and medicinal industry, and specifically relates to 6-aminolactose, preparation and application thereof. 6-aminolactose is shown as a formula (1). The preparation of the 6-aminolactose comprises: reacting modified lactose with sodium azide at 70-80 DEG C for 16-24 h, and purifying to obtain 6-azido-2,3,4-acetyllactose, wherein the molar amount of sodium azide is 2-3 times of that of lactose; reducing 6-azido-2,3,4-acetyllactose by employing triphenyl phosphine to obtain 6-amino-2,3,4-acetyllactose, wherein the molar ratio of triphenyl phosphine to lactose is 4:1; and performing hydrazinolysis or hydrolysis reaction to obtain 6-aminolactose. The synthetic steps are simple, the preparation method is easy to popularize, and demanded equipment and raw materials are easily available. 6-aminolactose obtained by employing the effective synthetic means is easy to purify because acetyl is used for protecting the product. The synthetic steps are simple, the preparation method is easy to popularize, and demanded equipment and raw materials are easily available. The obtained product is widely applicable to fields such as biology, medicine, foodstuff, chemical engineering and the like. The formula (1) is shown in the specification.
PURPOSE:To obtain a photographic processing agent capable of being easily transported and stored, appropriate for an automatic liq. preparation replenishing mechanism and with the environmental pollution reduced by mixing >=2 kinds of the powdery chemicals to be used as a photographic processing agent and granulating the mixture with a specified powdery chemical. CONSTITUTION:Two or more kinds of the powdery chemicals to be used as a photographic processing agent are mixed, the mixture is granulated with a powdery chemical so that the water content including water of crystallization is controlled to <=10% of the total weight of the granulated material. In this case, an ordinary granulation aid is preferably used, and the water content including water of crystallization is controlled to <=10%, preferably to <=5% or more preferably to <=1% when water is used. Besides, water, alkali or acid- soluble polymers can be used. Consequently, the transportation and storage are facilitated, the agent is highly soluble and appropriate for a miniaturized automatic liq. preparation replenishing mechanism, the grain strength is increased, the powder is not released due to disintegration, the powdery agent is not left in the package, and further environmental pollution is reduced.
PURPOSE:To prepare 5-fluorouracil useful as a carcinostatic agent for cutaneous cancer, etc., economically, in high yield, by thermally decomposing 6-hexafluoroisopropoxy-5-fluoro-5,6-dihydrouracil (a novel compound) at a specific temperature. CONSTITUTION:The novel compound of formula III obtained by the reaction of the compound of formula I with the compound of formula II and fluorine gas is heated at 100 deg.C- the decomposition temperature of the objective compound (282 deg.C) in the absence or presence of a solvent, preferably a solvent having a boiling point of >=100 deg.C, e.g. xylene, dimethylformamide, dimethylsulfoxide, acetic acid, liquid paraffin, etc. to obtain the objective compound of formula IV. The yield of the product from the starting substance of formula I is as high as about 95%. Since the compound of formula II is inert to fluorine gas under the reaction condition, free from corrosivity, and has high reaction rate and low boiling point (58.5 deg.C), the unreacted material can be easily recovered after the reaction.
Heart failure is a clinical syndrome characterized by symptoms of dyspnea, exercise intolerance and decreased quality of life. A weakness in both inspiratory and peripheral muscles is also reported. Aerobic training (AT) improves the functional status of HF patients (level of evidence IA). Additional benefits of inspiratory muscle training (IMT) and/or resistance training (RT) when combined with aerobic training (AT) in HF symptoms have also been found.

Four exercise groups will be studied in order to identify the optimum exercise program I. Aerobic-Resistance-Inspiratory training (ARIS) group II. Aerobic Training-Resistance Training (AT/RT) group III. Aerobic training-Inspiratory Muscle Training (AT/IMT) group IV. Aerobic Training (AT) group
A pharmaceutical composition containing the active substance atorvastatin in the form of oblong-shaped tablets with the length of 5 to 22 mm and the width of 2 to 11 mm or round tablets with the diameter of 3 to 16 mm, the core of which is constituted of compressed granulate and contains: i. Atorvastatin and/or at least one physiologically acceptable salt thereof in the quantity of 5 to 10% by weight, related to pure atorvastatin; ii. An organic or inorganic base selected from meglumine or an alkali metal hydroxide or their combination in the quantity of 0.01 to 7% by weight; iii. A pharmaceutically acceptable filler in the quantity of 20 to 90% by weight; iv. A disintegrant in the quantity of 0.5 to 50% by weight; provided with a coat that makes up 1 to 15% of the weight of the core, the selected base being uniformly distributed in the tablet core by means of spraying the same on the solid mixture in the granule production process. The composition can be obtained by a procedure consisting of the following steps: i. Mixing a mixture of atorvastatin, a filler and a disintegrant; ii. Dissolving a base in a mixture of water and a C 1  to C 3  alcohol in the quantity of 10 : 90 to 90 : 10 (water/alcohol, by weight); iii. Spraying the dry mixture with the base solution either in a masticating or fluidizing device; iv. Adapting the size of particles of the resulting granulate, preferably by re-sieving to the granule size of 0.1 to 1.5 mm; v. Adding other extragranular components to the granulate that will further improve its ability to be compressed into tablets; vi. Compressing the mixture; and vii. Applying a coat on the compressed tablets.
Each MICT session will consist of aerobic training regulated against an individualized load set to reach a moderate submaximal exercise intensity (i.e. power output is lower than power output at maximum oxygen uptake). Session duration for MICT is initially 30 min, including warm-up (5 min) and cool-down (5 min). The protocol enables controlled and systematic adjustments of training intensity by means of standardized criteria.
The V-Wave Shunt is a device placed across the interatrial septum (IAS) by cardiac catheterization which allows for the transfer of blood from the left atrium (LA) to right atrium (RA). The intended effect is to reduce excessive left-sided cardiac filling pressures in patients with advanced heart failure (HF) and thus improve symptoms related to pulmonary congestion. All patients in the study must meet all anatomic and clinical eligibility in the FDA approved indications for use of the MitraClip in functional mitral regurgitation (MR). All patients must have persistence of New York Heart Association (NYHA) class III or ambulatory class IV HF symptoms despite maximally tolerated guideline directed medical therapy (GDMT) as assessed by a Cardiologist specialist in advanced heart failure (HF). All patients will have reduced left ventricular (LV) ejection fraction (EF) ≥ 20% and ≤ 50% and at least moderate to severe 3-4+ MR with a functional or combined functional and degenerative mechanism. Despite MitraClip treatment and maximum GDMT, these patients are at high risk for recurrent HF events and readmission, and thus there is an unmet need for further therapies to improve outcomes in this patient population.

The existing transseptal puncture used for MitraClip placement will be used to place the V-Wave Shunt device after MitraClip placement.
Patients receive ICG dye SC and receive fluids IV over one hour and undergo SPY imaging and lymphedema assessment on day 1. Patients also receive ICG dye and undergo imaging and lymphedema assessments again at 1, 3, 6, and 12 months on study.
Patients in this arm will also receive the standard pre-drug initiation training followed by telephone follow up by an oncology certified chemotherapy nurse (OCN) at week one, two, and three. Patients will then have the standard 4 week follow up clinic visit.
The IgM treatment will be initiated as soon as possible after randomization (maximum allowed starting time 12h after randomization). The dose of IgM preparation will be 250mg/kg for 3 days, the dose will be administered in 24 hours in continuous infusion with a maximum infusion rate of 0,4 ml/kg (20mg/kg per hour) until reaching 250mg/kg.